France
Genomic Vision is a French biotech company dedicated to providing tools and services for visualizing and characterizing single DNA molecules. The company, founded in 2005, focuses on developing innovative diagnostic and drug discovery solutions using its proprietary nanotechnology for DNA analysis. Their applications primarily target cancer and acute diseases at the intersection of genome dynamics and human pathology. Genomic Vision employs Molecular Combing Technology, a powerful technique for direct visualization of single DNA molecules to detect quantitative and qualitative changes in the genome landscape, establishing their role in pathology.
The company's initial emphasis lies on early cancer detection and drug therapy monitoring, leveraging their unparalleled capability to discover genomic biomarkers related to various forms of cancer predisposition and development. Furthermore, Genomic Vision has made significant strides in analyzing DNA replication during cell division, offering a unique approach to evaluate the efficacy of new drugs on the cell cycle.
The most recent financial milestone for Genomic Vision was its Series B investment in July 25, 2008, marking an important stage in the company's growth and development within the field of Biotechnology. As of now, information regarding the specific investors in this round is not available.
